IPM Take
This is where personalised medicine becomes operationally real. An individualized neoantigen therapy is not pulled from a shelf. It depends on tumour tissue, sequencing, algorithmic neoantigen selection, manufacturing, immunotherapy timing and specialist follow-up. The five-year data make the science more convincing. They also make the delivery challenge impossible to ignore.
Executive Summary
At ASCO 2026, five-year follow-up data from the Phase IIb KEYNOTE-942/mRNA-4157-P201 study were presented for intismeran autogene, also known as mRNA-4157 or V940, in combination with pembrolizumab in patients with high-risk stage III/IV melanoma after complete resection. The direct announcement reported a median follow-up of 60.3 months. The combination reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 59% compared with pembrolizumab alone. The data were presented at ASCO 2026 and published simultaneously in the Journal of Clinical Oncology.
Why it matters
- Hospitals / providers: Need systems for tumour sampling, sequencing, manufacturing coordination and treatment scheduling.
- Regulators / HTA bodies: Must assess value for a therapy that is individualized rather than conventionally manufactured at scale.
- Patients / advocates: Should watch whether access is designed beyond a small number of highly specialised centres.
Melanoma has already been transformed by immunotherapy. Individualized neoantigen therapy adds another layer: treatment designed from the patient’s own tumour mutations.
The ASCO 2026 update is important because durability is one of the central questions for cancer vaccines. A short-term immune response is not enough. Patients, clinicians and payers need to know whether the benefit continues over time, especially in the adjuvant setting where the goal is preventing recurrence after surgery.
The five-year data suggest sustained reductions in recurrence and distant metastasis risk. That is scientifically important, but the implementation challenge is just as important. A personalised vaccine requires a chain of actions that must work quickly and reliably. Tissue must be obtained and sequenced. The therapy must be designed and manufactured. Patients must remain fit and eligible. Treatment must be coordinated with pembrolizumab and follow-up.
For IPM, the access lesson is clear: personalised cancer vaccines will not scale through approval alone. They need a pathway that is as personalised as the medicine.
